

WHAT IS CLAIMED IS:

26. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human melanocortin-4 receptor (MC-4R) agonist wherein the binding of the compound to the human MC-4R is characterized by an IC₅₀ less than 30 nanomolar (nM) and the binding of the compound to the human MC-1R is characterized by an IC₅₀ greater than 30 nM.
27. The method of Claim 26 wherein the binding of the compound to the human MC-1R is characterized by an IC₅₀ greater than 100 nM.
28. The method of Claim 26 wherein the binding of the compound to the human MC-1R is characterized by an IC₅₀ greater than 1000 nM.
29. The method of Claim 26 wherein the binding of the compound to the human MC-1R is characterized by an IC₅₀ greater than 2100 nM.
30. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human MC-4R agonist wherein the binding of the compound to the human MC-4R is characterized by an IC₅₀ less than 30 nM and the binding of the compound to the human MC-3R is characterized by an IC₅₀ greater than 30 nM.
31. The method of Claim 30 wherein the binding of the compound to the human MC-3R is characterized by an IC₅₀ greater than 100 nM.
32. The method of Claim 30 wherein the binding of the compound to the human MC-3R is characterized by an IC₅₀ greater than 540 nM.
33. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human MC-4R agonist wherein the binding of the compound to the human MC-4R is characterized by an IC₅₀ less than

Rule 1.124

TOTT 66406660

30 nM and the binding of the compound to the human MC-5R is characterized by an IC₅₀ greater than 30 nM.

9
34. The method of Claim 33 wherein the binding of the compound
5 to the human MC-5R is characterized by an IC₅₀ of greater than 100 nM.

10
35. The method of Claim 33 wherein the binding of the compound
to the human MC-5R is characterized by an IC₅₀ greater than 230 nM.

11
36. The method of Claim 26 wherein the compound is further
10 characterized by binding to each of the human MC-2R, MC-3R, and MC-5R with an
IC₅₀ greater than 30 nM.

12
37. The method of Claim 27 wherein the compound is further
15 characterized by binding to each of the human MC-2R, MC-3R, and MC-5R with an
IC₅₀ greater than 100 nM.

13
38. The method of Claim 28 wherein the compound is further
20 characterized by binding to each of the human MC-2R and MC-3R with an IC₅₀
greater than 540 nM and binding to the MC-5R with an IC₅₀ greater than 230 nM.

14
39. The method of Claim 36 wherein the compound is further
25 characterized by binding to any other human melanocortin receptor with an IC₅₀
greater than 30 nM.

15
40. The method of Claim 37 wherein the compound is further
characterized by binding to any other human melanocortin receptor with an IC₅₀
greater than 100 nM.

16
41. The method of Claim 38 wherein the compound is further
30 characterized by binding to any other human melanocortin receptor with an IC₅₀
greater than 500 nM.

17
42. A method of treating sexual dysfunction in a male or female
35 subject which comprises administering to the subject in need thereof a therapeutically

effective amount of a compound which is a human MC-4R agonist wherein the compound binds to the human MC-4R with a binding affinity at least 10-fold higher than the compound binds to each of the human MC-1R, MC-2R, MC-3R, and MC-5R.

5

¹⁸
~~43~~. The method of Claim 42 wherein the compound binds to the human MC-4R with a binding affinity at least 100-fold higher than the compound binds to each of the human MC-1R, MC-2R, MC-3R, and MC-5R.

10

¹⁹
~~44~~. The method of Claim 42 wherein the compound binds to the human MC-4R with a binding affinity at least 1000-fold higher than the compound binds to each of the human MC-1R and MC-2R, at least 580-fold higher than the compound binds to the human MC-3R, and at least 250-fold higher than the compound binds to the human MC-5R.

15

²⁰
~~45~~. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human MC-4R agonist wherein the compound binds to the human MC-4R with a binding affinity at least 10-fold higher than the compound binds to any other human melanocortin receptor.

20

²¹
~~46~~. The method of Claim 45 wherein the compound binds to the human MC-4R with a binding affinity at least 100-fold higher than the compound binds to any other human melanocortin receptor.

25

²²
~~47~~. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human MC-4R agonist wherein the functional activity at the MC-4R is characterized by an EC₅₀ less than 10 nM and the functional activity at the MC-1R is characterized by an EC₅₀ greater than 10 nM.

30

²³
~~48~~. The method of Claim 47 wherein the functional activity of the compound at the MC-1R is characterized by an EC₅₀ greater than 100 nM.

- 24
49. The method of Claim 47 wherein the functional activity of the compound at the MC-1R is characterized by an EC₅₀ greater than 1200 nM.
- 25
50. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human MC-4R agonist wherein the functional activity at the MC-4R is characterized by an EC₅₀ less than 10 nM and the functional activity at the MC-3R is characterized by an EC₅₀ greater than 10 nM.
- 24
51. The method of Claim 50 wherein the functional activity of the compound at the MC-3R is characterized by an EC₅₀ greater than 100 nM.
- 23
52. The method of Claim 50 wherein the functional activity of the compound at the MC-3R is characterized by an EC₅₀ greater than 1200 nM.
- 28
53. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human MC-4R agonist wherein the functional activity at the MC-4R is characterized by an EC₅₀ less than 10 nM and the functional activity at the MC-5R is characterized by an EC₅₀ greater than 10 nM.
- 29
54. The method of Claim 53 wherein the functional activity of the compound at the MC-5R is characterized by an EC₅₀ greater than 100 nM.
- 30
55. The method of Claim 53 wherein the functional activity of the compound at the MC-5R is characterized by an EC₅₀ greater than 520 nM.
- 31
56. The method of Claim 47 wherein the compound is further characterized by having a functional activity at each of the human MC-2R, MC-3R, and MC-5R with an EC₅₀ greater than 10 nM.
- 32
57. The method of Claim 48 wherein the compound is further characterized by having a functional activity at each of the human MC-2R, MC-3R, and MC-5R with an EC₅₀ greater than 100 nM.

33
38. The method of Claim 49 wherein the compound is further characterized by having a functional activity at the human MC-2R and MC-3R with an EC₅₀ greater than 1200 nM and a functional activity at the human MC-5R with an EC₅₀ greater than 520 nM.

5

34
35. A method of treating sexual dysfunction in a male or female subject which comprises administering to the subject in need thereof a therapeutically effective amount of a compound which is a human MC-4R agonist wherein the functional activity at the human MC-4R is characterized by an EC₅₀ at least 10-fold lower than the functional activity at each of the human MC-1R, MC-2R, MC-3R, and MC-5R.

10

35
36. The method of Claim 59 wherein the functional activity at the human MC-4R is characterized by an EC₅₀ at least 100-fold lower than the functional activity at each of the human MC-1R, MC-2R, MC-3R, and MC-5R.

15

36
37. A method for the oral treatment of sexual dysfunction in a male or female subject which comprises the oral administration to the subject in need thereof a therapeutically effective amount of a compound which is an agonist of the human MC-4R.

20

37
38. The method of Claim 61 wherein the compound is a selective agonist of the human MC-4R.

25

38
39. The method of Claim 61 wherein the sexual dysfunction is erectile dysfunction.

add
a1